Ziprasidone, Olanzapine

PreclinicalSmall molecule

WWashington University School of Medicine

Ziprasidone, Olanzapine is one of 4 small molecule programs targeting Olanzapine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OlanzapineCompleted

OlanzapinePreclinical

Completed

Competition

Competitive Landscape

3 competitors in Olanzapine

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

30 2

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 3

Decadron

AAspen Global Incorporated

Preclinical

1 4

Ziprasidone, Olanzapine

WWashington University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Olanzapine1 trial

Pfizer/IVGTT/Ziprasidone/Olanzapine

Completed·WWashington University School of Medicine·N/A·NCT00205725·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ziprasidone, Olanzapine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ziprasidone, Olanzapine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ziprasidone, Olanzapine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWashington University School of Medicine

Ziprasidone, Olanzapine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Olanzapine1 trial

References

Drug Info

Quick Facts

Related News